| Unknown | Prediction of Lymph Node Invasion for Prostate Adenocarcinoma NCT04909957 | University Hospital, Brest | — |
| Active Not Recruiting | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in NCT04909294 | Centre Georges Francois Leclerc | N/A |
| Recruiting | Prospective Prostate Cancer and Patient-reported Outcomes Registry NCT04694924 | Universitaire Ziekenhuizen KU Leuven | — |
| Unknown | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adeno NCT04586543 | László Mangel | Phase 2 |
| Unknown | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer NCT04097002 | Orca Therapeutics B.V. | Phase 1 / Phase 2 |
| Terminated | Muscadine Plus (MPX) In Men With Prostate Cancer NCT03535675 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 3 |
| Completed | Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Ca NCT03686683 | Dendreon | Phase 3 |
| Active Not Recruiting | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) NCT03689699 | Mark Stein | Phase 1 / Phase 2 |
| Active Not Recruiting | Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer NCT03624660 | University of Florida | Phase 2 |
| Active Not Recruiting | Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer NCT03511196 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Terminated | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes NCT03432897 | Brown University | Phase 2 |
| Completed | Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer NCT03077659 | NanOlogy, LLC | Phase 2 |
| Terminated | Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer NCT03327662 | Institute of Cancer Research, United Kingdom | Phase 3 |
| Completed | Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer NCT02163317 | Case Comprehensive Cancer Center | N/A |
| Completed | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer NCT02278185 | University of Colorado, Denver | Phase 2 |
| Completed | Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy NCT02523924 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy NCT02203695 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Completed | Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer NCT02048150 | City of Hope Medical Center | Phase 1 |
| Unknown | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC NCT02525068 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Active Not Recruiting | Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer NCT02176902 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Pilot Study of DRibble Vaccine for Prostate Cancer Patients NCT02234921 | UbiVac | Phase 1 |
| Completed | Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound NCT02225925 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer NCT02217709 | University of Southern California | Phase 2 |
| Completed | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer NCT02184533 | Stanford University | Phase 1 |
| Completed | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate C NCT02058706 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine NCT01992016 | University of Colorado, Denver | N/A |
| Active Not Recruiting | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prosta NCT02023463 | Thomas Jefferson University | Phase 1 |
| Active Not Recruiting | Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer NCT02296229 | Jonsson Comprehensive Cancer Center | N/A |
| Unknown | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metasta NCT01949337 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Under NCT01912820 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Enzalutamide in Patients With High-risk Prostate Cancer NCT01927627 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Docetaxel and Lycopene in Metastatic Prostate Cancer NCT01949519 | Medical University of South Carolina | Phase 1 |
| Terminated | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01866423 | University of Southern California | Phase 2 |
| Completed | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT01848067 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Completed | A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radica NCT01832259 | University of Utah | Phase 2 |
| Terminated | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cance NCT01913015 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Cabozantinib in Men With Castration-Resistant Prostate Cancer NCT01703065 | University of Washington | Phase 2 |
| Completed | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate NCT01807065 | City of Hope Medical Center | Phase 2 |
| Completed | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate NCT02064036 | University of California, Davis | Phase 1 |
| Completed | Radiation and Androgen Ablation for Prostate Cancer NCT01517451 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Unknown | Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prosta NCT02761889 | Fundacao Champalimaud | N/A |
| Completed | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer NCT01812668 | Barbara Ann Karmanos Cancer Institute | N/A |
| Terminated | Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer NCT01795365 | Centre Hospitalier Universitaire Vaudois | N/A |
| Active Not Recruiting | High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer NCT01655836 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Unknown | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer NCT01682772 | Institute of Cancer Research, United Kingdom | Phase 2 |
| Completed | High-Dose Stereotactic Radiation for Prostate Cancer NCT01664130 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer NCT01859689 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resis NCT01498978 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer NCT01533246 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer NCT01174199 | Roswell Park Cancer Institute | Phase 1 |
| Unknown | EPISPOT Detection of Circulating Prostate Cells Among Adenocarcinoma Patients NCT01402154 | Centre Hospitalier Universitaire de Nīmes | — |
| Completed | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery NCT01433913 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01468532 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer NCT01054079 | Wake Forest University Health Sciences | Phase 2 |
| Completed | The Prostate Immobilization Device Study NCT01408706 | James Taylor | N/A |
| Withdrawn | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling NCT01368003 | Toni Choueiri, MD | Phase 2 |
| Terminated | Genistein in Treating Patients With Prostate Cancer NCT01126879 | Northwestern University | Phase 2 |
| Completed | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Tre NCT01270880 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients NCT01882985 | University of California, Irvine | Phase 2 |
| Completed | Sulforaphane in Treating Patients With Recurrent Prostate Cancer NCT01228084 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate C NCT01094288 | Millennium Pharmaceuticals, Inc. | Phase 1 |
| Terminated | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer NCT01200810 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer NCT01117935 | Virginia Commonwealth University | N/A |
| Terminated | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Can NCT01093183 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer NCT01023061 | University of Washington | Phase 2 |
| Completed | Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer NCT01050842 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate NCT01255891 | Dr. Tamim Niazi | Phase 2 |
| Terminated | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients NCT00879619 | John P. Fruehauf | Phase 1 / Phase 2 |
| Completed | R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Can NCT00666666 | National Cancer Institute (NCI) | Phase 2 |
| Completed | MRI-Guided Radiation Therapy in Treating Patients Who Have Undergone Surgery to Remove the Prostate NCT01028885 | Abramson Cancer Center at Penn Medicine | Phase 1 |
| Completed | Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer NCT02237612 | University of Southern California | N/A |
| Withdrawn | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate NCT00598858 | John P. Fruehauf | Phase 2 |
| Completed | Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer NCT00450749 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That D NCT00527124 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer NCT00512668 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metas NCT00520481 | Eli Lilly and Company | Phase 2 |
| Completed | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer NCT00570700 | University of California, Irvine | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy NCT01656304 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Defined Green Tea Catechins in Treating Patients With Prostate Cancer Undergoing Surgery to Remove the Prostat NCT00459407 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prosta NCT00430235 | British Columbia Cancer Agency | Phase 2 |
| Completed | Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping NCT00608920 | Washington University School of Medicine | N/A |
| Completed | Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer NCT00450229 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery NCT00438464 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostat NCT00466752 | University of Washington | Phase 2 |
| Completed | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy NCT00337077 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatec NCT00321646 | Mary-Ellen Taplin, MD | Phase 2 |
| Completed | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy NCT00331344 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate NCT00915122 | University Health Network, Toronto | Phase 1 / Phase 2 |
| Completed | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel NCT00096499 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Re NCT00110214 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer NCT00109811 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy NCT00118092 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic Prostate Cancer NCT00087139 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer NCT00080899 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatmen NCT00165399 | Dana-Farber Cancer Institute | Phase 2 |
| Unknown | A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel NCT00764166 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate NCT00058084 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Perifosine in Treating Patients With Recurrent Prostate Cancer NCT00058214 | National Cancer Institute (NCI) | Phase 2 |
| Completed | High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer NCT00243321 | Virginia Commonwealth University | N/A |
| Completed | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy NCT00040755 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer NCT00039104 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone NCT00181558 | Massachusetts General Hospital | Phase 2 |
| Completed | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer NCT00016107 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pre-Prostatectomy Celecoxib or Placebo NCT02840162 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer NCT00182052 | Massachusetts General Hospital | Phase 3 |
| Completed | Study of Histrelin Subdermal Implant in Patients With Prostate Cancer NCT01394263 | Endo Pharmaceuticals | Phase 3 |
| Completed | Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer NCT01697384 | Endo Pharmaceuticals | Phase 3 |
| Terminated | Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer NCT00005067 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) NCT00005039 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer NCT00020046 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Terminated | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer NCT00019695 | National Cancer Institute (NCI) | Phase 2 |
| No Longer Available | Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer NCT00636259 | AstraZeneca | — |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer NCT00003517 | Burzynski Research Institute | Phase 2 |